Edgewise Therapeutics, Inc. - Common Stock (EWTX)

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

The company will publish very encouraging results from a clinical trial soon, one pundit believes.

A full exit during a volatile stretch raises a sharper question than timing alone.

The company just might have a winner on its hands with a pipeline heart disease treatment.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said.

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Edgewise Therapeutics (EWTX) reports Q2 2025 EPS beat at -$0.34 vs. -$0.42 estimates, sparking a 5% pre-market rally. Clinical progress in muscle disease treatments drives optimism.

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.